Introduction
Cancer poses a major threat to public health worldwide. It was the cause of 8.2 million deaths globally in 2013 and has become the leading cause of mortality ranking second only to cardiovascular disease. 1 Recently published data shows that cancer incidence and cancer mortality in China has significantly increased during the past few decades, and cancer is now the leading cause of death in China. 2 A 2016 publication 3 estimated that about 4,292,000 new cancer cases and 2,814,000 cancer deaths would occur in China for 2015. Multiple factors including genetic, environmental and nutritional status are associated with cancer incidence and mortality. Serum uric acid (SUA) is the end product of purine metabolism via xanthine oxidoreductase (XOR) and is mainly eliminated by the kidney and the intestinal tract. Previous studies have shown that elevated SUA is linked to hypertension, 4 diabetes mellitus 5 and metabolism syndrome. 6 In addition, research from the past recent decades has shown that SUA influences cancer incidence and related mortality. It has been proposed that the antioxidant properties of SUA may play a crucial role in cancer etiology by acting as a scavenger of oxygen free radicals, thereby protecting against carcinogenesis. 7 In contrast, many large epidemiological prospective investigations on western populations have drawn an opposite conclusion: that SUA increases the risk of cancer and related mortality. Analyses from a large prospective cohort of Austrian adults found the association of SUA with risk of cancer mortality and incidence presented a dose-response relationship. 8 These studies conducted on both male and female Austrian cohorts confirmed that high SUA (>6.71 mg/dl in men and >5.41 mg/dl in women) measured at baseline was an independent risk factor for death from all cancers. 8, 9 Strasak et al.
revealed a moderately J-shaped effect of SUA on risk of overall cancer incidence. 10 More recently, a meta-analysis indicated that a positive association between elevated SUA levels and total cancer incidence was observed only in males but not females. 11 Moreover, the relationship between SUA levels and cancer incidence and mortality is unknown in populations from mainland China. In addition, the impact of SUA on cancer incidence in females is unclear as few cohort studies have investigated this relationship in women.
To explore the potential role of SUA on cancer incidence and mortality regarding gender-specific differences in China, we conducted a detailed analysis of cancer as a pre-specified endpoint using data from the China Stroke Primary Prevention Trial (CSPPT), 12 a large prospective randomized trial designed to test the effect of combined folic acid and enalapril on the prevention of primary stroke among hypertensive patients in China.
Participants and Methods

Participants
Detailed inclusion and exclusion criteria of the CSPPT trial have been reported elsewhere. 12 In brief, the CSPPT was a large, multi-community, prospective, randomized, double-blinded, controlled trial conducted from May 19, 2008 to August 24, 2013 in 32 communities in Lianyungang, Jiangsu province and Anqing, Anhui province, China. Eligible participants were men and women aged 45-to 75-year old who had hypertension, defined as seated resting systolic blood pressure (SBP) 140 mmHg or diastolic blood pressure (DBP) 90 mmHg at both the screening and recruitment visit, or who were on an antihypertensive medication. Patients with a physician diagnosed history of stroke, myocardial infarction (MI), heart failure, post-coronary revascularization or congenital heart disease were excluded. The CSPPT was approved by the Ethics Committee of the Institute of Biomedicine, Anhui Medical University, Hefei, China (FWA assurance number: FWA00001263) and registered with ClinicalTrials.gov, NCT00794885. All participants gave written informed consent.
Procedure
The rationale and study design for the CSPPT have been published in detail elsewhere. 12 Eligible participants were stratified by the MTHFR C677T genotype and randomly assigned to one of two groups in a global 1:1 ratio: the enalapril-folic acid group in which patients were given one What's new? Serum uric acid (SUA), the end product of purine metabolism, is elevated in various diseases, among them hypertension and cancer. Previous studies, however, have proposed conflicting roles for SUA in cancer, with elevated SUA either protecting against or contributing to cancer risk. In the present evaluation of SUA and cancer in a cohort of Chinese adults with hypertension, elevated SUA was found to be positively associated with overall cancer risk, risk of digestive organ cancers and cancer mortality. The association was specific for enalapril-treated patients. By contrast, cancer risk was attenuated among patients taking enalapril with folic acid supplementation.
fixed-dose combination tablet containing 10 mg enalapril and 0.8 mg folic acid (n 5 10,354); or the enalapril group in which patients were given 10 mg enalapril alone (n 5 10,348). For this study, we further excluded 125 participants (0.6%) with missing or incomplete SUA measurements at baseline, leaving a total of 10,286 and 10,291 participants in the enalapril group and enalapril-folic acid group, respectively (details are shown in Supporting Information Figure  1 ). Participants were then scheduled for follow-up every 3 months. During the follow-up period, concomitant use of other antihypertensive medications (mainly calcium channel blockers or diuretics) was allowed, but not B vitamins.
Measurements
Serum folic acid and vitamin B 12 were measured using a chemiluminescent immunoassay (New Industrial, Shenzhen, China). Fasting lipid profiles, SUA, serum creatinine, glucose and homocysteine at both the baseline and the exit visits were measured using automatic clinical analyzers (Beckman Coulter, CA) at the central laboratory of the National Clinical Research Center for Kidney Disease, Nanfang Hospital in Guangzhou, China.
Resting blood pressure was measured at baseline and every 3 months thereafter. Information on smoking status and alcohol consumption (current, former, never) for each participant was recorded at baseline and at the last visit. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared. Subjects were not asked to make any changes to diet during the study. Drug compliance was assessed by counting returned tablets at each visit. Estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formulation, based on the findings by Kong et al. 13 who demonstrated that CKD-EPI performs better than MDRD in a Chinese population.
Endpoints
Originally, the CSPPT was designed to investigate the efficacy of folic acid supplementation on the primary prevention of stroke. While incident cancer was a pre-specified endpoint of the CSPPT, it was the only endpoint of this secondary analysis. A cancer diagnosis was based on positive pathologic findings (pathological reports and medical records from hospitals in which pathological results were cited) or specific clinical manifestations. When pathological reports were not available, suspicious cases were independently reviewed by two oncologists. A cancer diagnosis was determined only if both physicians came to the same clinical diagnosis based on clinical manifestations and medical examinations. All cancer events were further reviewed and confirmed by an independent Endpoint Adjudication Committee, whose members were unaware of study-group assignments.
Statistical analysis
The efficacy index for an outcome was the time from randomization to the first event of incident cancer; one-way analysis of variance and v 2 tests were used for comparisons between SUA tertiles in continuous and categorical variables. The effects of SUA concentrations on trial outcomes were evaluated using Cox proportional hazards regression with adjustment for prespecified factors including age, gender, study center, BMI, history of diabetes mellitus, smoking status and alcohol consumption at baseline, on-treatment SBP, baseline eGFR, vitamin B 12 (B 12 ), homocysteine (Hcy), serum folate, total cholesterol (TC) and MTHFR 677 T polymorphisms. Groups were further subdivided into three tertiles (first, second and third) based on serum SUA levels by gender: Males: <5.5[reference], 5.5-6.7, 6.7 mg/dl; Females: <4.5[reference], 4.5-5.4, 5.4 mg/dl). Crude cumulative incidence across SUA tertiles was examined via Kaplan-Meier curves 14 ( Fig. 1) . We further explored the association of SUA and cancer related mortality as well as major subtypes of cancers when adequate numbers of cases were available (including digestive cancer, the most common subtype in our study, cancer of the respiratory system and breast). A global v 2 test was used to assess the proportional hazards assumption, which was not violated (p values > 0.05). Stratification analysis was made for important co-variables. The following potential effect modifiers were considered: age (<60, 60 years), gender, tobacco use and alcohol consumption at baseline (never, ever and current), MTHFR C677T genotypes (CC, CT or TT) and diuretic drug use during the followup period (yes/no). Two-tailed probability values of <0.05 were considered to indicate statistical significance. All statistical analyses were performed using Empowerstats (www.empowerstats.com) and R software (http://www.R-project.org).
Results
Study participants and baseline characteristics
The demographic and clinical parameters of participants are presented in Table 1 . A total of 20,577 hypertensive adults from the CSPPT with complete and valid data on SUA at baseline were eligible for this study. Patients were prospectively followed for a median time of 4.5 years. Patients with higher SUA levels tended to be older, had a higher frequency of alcohol intake, hyperlipidemia history and, had higher blood pressure at baseline and during the trial period as well as higher baseline BMI, B 12 , folate, Hcy and TC levels, but had less tobacco use, a lower frequency of diabetic history, the MTHFR 677TT mutation and lower eGFR levels.
Association between SUA and risk of cancer After a median of 4.5 years, a total of 232 incident cancer cases had been observed (116 cases for each treatment group). As a continuous variable, baseline uric acid levels were independently and positively associated with risk of total cancer in the enalapril group [HR: 1.12, (95% CI: 1.03-1.22), p 5 0.006]. In the enalapril folic acid group, SUA was not associated with an increased risk for total cancer incidence (p values > 0.05, p for interaction 5 0.026). We subsequently explored the relationship between cancer risk and SUA tertiles. The adjusted hazards ratios (HR) for the highest and middle tertiles compared 
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to the lowest tertile of SUA were 1.57 (0.95, 2.61) and 1.59 (0.99, 2.58), respectively in the enalapril group. When combined, those patients in the upper tertiles had a 58% higher cancer risk than the lowest tertile [T2 1 T3: HR: 1.58, (95% CI: 1.02-2.47), p 5 0.041]. No SUA tertile was associated with an increased risk for total cancer incidence in the enalapril folic acid group (p for interaction 5 0.016). Details are shown in Table 2 . Kaplan-Meier curves showed that patients within the upper tertiles of SUA had a higher cumulative incidence of cancer in the enalapril group, but not the enalapril-folic acid group (Figs. 1a and 1b) .
Association between SUA and risk of major cancer subtypes and cancer mortality Figure 2 and Supporting Information Table 1 display the association between SUA and site specific cancer and cancer mortality. In cancer site-specific analyses, we explored SUA levels and the cancer risk of digestive organs (including esophagus, stomach, colorectum, liver and pancreas) and other cancer (including cancer of the respiratory system and breast). Using Cox proportional hazards models, after adjusting for possible confounding factors, SUA as a continuous variable significantly increased the cancer risk of digestive Table 2 .
Stratified analysis of overall cancer incidence
Stratified analyses were performed by age (<60, 60 years), gender, smoking status and alcohol consumption status (never, ever and current), MTHFR C677T genotypes (CC, CT and TT) and diuretic drug use during the follow-up period (yes/no). In our cohort, the impact of SUA on carcinogenesis was not affected by age, gender, MTHFR C677T genotype or diuretic drug use during the follow-up period (p for all interactions > 0.05) for either treatment group. In men, there were no significant interactions between SUA levels and smoking status or alcohol consumption status in either treatment group (p for all interactions >0.05). We were unable to explore the effect of smoking status and alcohol consumption on cancer risk associated with elevated SUA in women due to the small numbers of female active smokers or drinkers in this cohort. Results are presented in Figure 3 .
Discussion
The role of SUA in carcinogenesis is controversial and may differ according to gender. This study aimed to assess the association between SUA and subsequent cancer events and related mortality in a large, prospective cohort study performed in a community-based, Chinese hypertensive population. In the enalapril group, SUA levels were positively related to risk of overall cancer. High levels of SUA were associated with an increased cancer risk of digestive organs as well as cancer mortality, while folic acid supplementation attenuated the risk of overall cancer and digestive cancer.
Our results are in accordance with most large, prospective cohort studies although one cohort study conducted by Taghizadeh et al. 15 demonstrated that higher levels of SUA were related to a lower risk of cancer mortality, supporting a protective role of SUA in the risk of cancer mortality. Kolonel et al. 16 found elevated baseline SUA levels were not associated with the risk of overall cancer and most subtypes of cancer, but were only positively associated with the risk of developing prostate cancer in Japanese men [adjusted RR: 1.5, (95% CI: 1.1-2.1)]. The Scottish Heart Health Extended Cohort Study 17 showed that elevated SUA is a risk for cancer and is gender-specific. A meta-analysis 11 also concluded that high SUA levels are positively associated with cancer incidence and mortality, and differ by gender. However, we found no studies from China and few studies on cancer incidence risk among women. To elucidate the impact of SUA on cancer in China and shed light on gender effects, we estimated the association between SUA and the risk of cancer in both men and women. Our results suggest that elevated SUA is independently and positively associated with an increased risk of cancer in people without folic acid supplementation. However, no significant gender specific differences were discovered in this study.
We did not find a positive association between elevated SUA and risk of total cancer, major subtypes of cancer or cancer mortality in the enalapril-folic acid group. As a post hoc analysis of a large randomized control trial, patients had very similar clinical characteristics at baseline in the two different treatment groups. The only difference between the two groups is one received folic acid supplementation and the other did not. Thus, these results suggest an effect modification of folic acid supplementation on cancer risk associated with elevated SUA, particularly overall cancer and digestive cancer (p for interaction values < 0.05). Due to a limited number of cases, we did not have enough statistical power to verify our hypothesis. In our recent publication from the same cohort, 18 we found that folic acid supplementation did not reduce cancer risk in the whole study population, but there was a reduction in cancer risk in participants with the MTHFR C677T genotype accompanied with low baseline folate levels. A meta-analysis 19 concluded that women with daily dietary folate intake between 153 and 400 lg showed a significantly reduced breast cancer risk compared with those whose folate intake was <153 lg, but not for those whose intake was >400 lg. These findings suggest that the appropriate dose of folic acid supplementation does not increase cancer risk, but protects against carcinogenesis associated with high SUA. It may be that folate protects against certain types of cancer by providing a methyl group necessary for many biological reactions. Or, folic acid supplementation may reduce SUA concentrations, 20, 21 which would help explain the different effect of SUA on cancer risk in the two groups. Further studies are needed to clarify the mechanism.
The method of impact of SUA on cancer is also unclear. XOR is a crucial enzyme that catalyzes purines (mostly derived from diet) to form the main end product of uric acid. To date, studies have found that decreased XOR activity or poor XOR expression is associated with a poorly differentiated tumor and worsened clinical prognosis. While high levels of XOR can stimulate tumor differentiation and depress metastasis, 22 it appears that high SUA and relative XOR enzyme activity may be causally and directly related to cancer initiation and progression. However, SUA measurement is influenced by various metabolic, physiologic and environmental factors. Co-determining factors of SUA including alcohol consumption, use of diuretics and kidney function decline, may influence the results. Our study adjusted for alcohol consumption and kidney function in our models. The stratification analysis did not find an interaction of diuretic use on cancer risk related to SUA. Taken together, it is unlikely that the impact of high SUA on cancer risk was due to the above causes. It is well known that markedly elevated levels of SUA are frequently observed in cancer cases as a result of increased nucleic acid turnover in the rapidly proliferating tumor tissue. 23 In an effort to eliminate possible effects of severe preclinical disease, we excluded subjects with baseline SUA > 12 mg/dl, and found that elevated SUA still increased the risk of cancer, especially digestive cancer and cancer mortality for subjects in the enalapril group. Our study showed that a high level of SUA is an independent predictor of the risk of cancer, especially digestive cancer and cancer mortality in areas without folic-acid fortification.
The major strength of our current study is that we simultaneously evaluated the association between SUA levels and risk of cancer in both males and females, enabling us to estimate any gender-specific differences in this field. It is also the first cohort study to evaluate the effect of elevated SUA on carcinogenesis and cancer mortality in mainland China. Another strength is the parallel comparison of the association among patients with and without folic acid supplementation, providing insight into the potential interaction effect of SUA and folate supplementation.
Our study also had some limitations. First, the JapanHawaii Caner Study 16 reported that the association between SUA and cancer was strongest for cases diagnosed in the first 10 years, during which the effect size was not significantly changed. Thus, we believe that a longer follow-up time would not increase the odds. We observed a limited number of cases and deaths during the median follow up of 4.5 years in our cohort, thereby limiting the investigation of the impact of SUA on risk of more subtypes of caner and cancer mortality. We believe that longer follow-up duration could accumulate more cases providing a more definitive answer regarding the risk of different cancer subtypes such as, nervous system cancer, urological cancer and hematologic cancer or cancer risk among different SUA concentrations. Additionally, for the same reason, we could not thoroughly investigate the interaction of SUA and tobacco use and alcohol consumption in females. Chou et al. 24 reported that longitudinal changes in SUA can fluctuate. However, we were unable to evaluate the effect of SUA fluctuations on cancer risk because repeated SUA measurements were not available for the entire CSPPT cohort. Future studies with repeated SUA measurements will help to estimate the consistency of a single measurement. Finally, as this was a post hoc analysis of a hypertensive cohort, we compared the SUA levels in our cohort to that of a Japanese general population 25 and found the SUA levels in our cohort to be 0.3 and 0.6 mg/dl higher in men and women, respectively. However, this does not influence our conclusion as we defined low and high SUA according to the levels in our cohort. As our results are consistent with that of previous studies conducted among the general population and concluding that high SUA increases the risk of cancer, 8, 11, 17 the generalizability of our findings to non-hypertensive adults or populations seems reasonable.
Conclusions
In brief, our results from the CSPPT demonstrated that higher SUA levels are independently and positively associated with an increased risk of total cancer incidence, digestive cancer and cancer mortality in hypertensive Chinese as indicated in subjects from the enalapril group. This association can be modified by a small dosage of daily folic acid supplementation, especially for overall cancer and digestive cancer. These findings have important clinical and public health implications. As SUA is a common and easily available measurement in clinical activity, it is a convenient and feasible way to identify those patients who are at high risk of developing cancer and with poor prognosis.
